New Psychedelic Therapy AKO004 Under Development by Akome

A new psychedelic drug formulation called AKO004 is now under development by Akome Biotech, a wholly owned subsidiary of Core One Labs, as a potential treatment for Parkinson’s disease. The company has filed a provisional patent application for AKO004 with the U.S. Patent and Trademark Office. The AKO004…

Patent Request Filed for Cannabis-based Treatments for Parkinson’s and Like Diseases

Growblox Sciences has filed the first of several likely patent applications for cannabis-based compounds developed by Growblox Life Sciences, its wholly owned subsidiary. The application applies to pharmaceutical-grade mixtures that might be used to treat patients with neurodegeneration, especially those with Parkinson’s disease. Growblox Life Sciences is focused on researching and developing cannabis-based medicines.  The company uses various…